Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L. Telli, Andrea L. Richardson, Paula D. Ryan et al.|Clinical Cancer Research|2016Cited by 1.2k
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast CancerDaniel P. Silver, Judy E. Garber, Andrea L. Richardson et al.|Journal of Clinical Oncology|2010Cited by 983
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging AgentsNicolai J. Birkbak, Andrea L. Richardson, Zhigang C. Wang et al.|Cancer Discovery|2012Cited by 684
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk AssessmentAndrea Desmond, Leif W. Ellisen, Allison W. Kurian et al.|JAMA Oncology|2015Cited by 334
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancerAnita K. Mehta, Jennifer L. Guerriero, Emily Cheney et al.|Nature Cancer|2020Cited by 271